The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediated ex vivo platelet function in acute myocardial infarction

Platelets

Volumn 20, Issue 5, 2009, Pages 334-340

  Spiel, Alexander O ^a   Mayr, Florian B ^a,b   Ladani, Nathalie ^a   Wagner, Patricia G ^c   Schaub, Robert G ^c   Gilbert, James C ^c   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Archemix Corporation   (United States)

Author keywords

Aptamers; Myocardial infarction; Platelets; Thrombosis; von Willebrand factor

Indexed keywords

ADENOSINE DIPHOSPHATE; APTAMER; ARACHIDONIC ACID; ARC 1779; COLLAGEN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; HUMAN; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOGENESIS;

ADULT; AGE FACTORS; AGED; APTAMERS, NUCLEOTIDE; BLOOD CELLS; BLOOD PLATELETS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 68649114583     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100903085927     Document Type: Article

References (31)

1. Blann A. von Willebrand factor and the endothelium in vascular disease. Br J Biomed Sci 1993;50:125-134. (Pubitemid 23316848)
2. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: Focus on acute coronary syndromes. Circulation 2008;117:1449-1459.
3. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006;4:1186-1193. (Pubitemid 43756691)
4. Li M, Goto S, Sakai H, Kim JY, Ichikawa N, Yoshida M, Ikeda Y, Handa S. Plasma concentration of von Willebrand factor in acute myocardial infarction. Thromb Haemost 2000;84:204-209. (Pubitemid 30601464)
5. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998;98:294-299. (Pubitemid 28348050)
6. Ray KK, Morrow DA, Gibson CM, Murphy S, Antman EM, Braunwald E. Predictors of the rise in vWF after ST elevation myocardial infarction: Implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy. Eur Heart J 2005;26:440-446. (Pubitemid 40314759)
7. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116:2678-2686. (Pubitemid 350291240)
8. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-1397. (Pubitemid 39238016)
9. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B. Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003;102:4594-4599. (Pubitemid 37494129)
10. Fuchs I, Frossard M, Spiel A, Riedmuller E, Laggner AN, Jilma B. Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS. J Thromb Haemost 2006;4:2547-2552 (Pubitemid 44741545)
11. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C. et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 2006;48:2178-2185 (Pubitemid 44873056)
12. Christie DJ, Kottke-Marchant K, Gorman RT. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008;19:104-110 (Pubitemid 351302380)
13. Jilma B. Platelet function analyzer (PFA-100): A tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163. (Pubitemid 32812228)
14. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 2002;13:493-497. (Pubitemid 35373664)
15. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.
16. Pidcock M, Harrison P. Can the PFA-100 be modified to detect P2Y12 inhibition?. J Thromb Haemost 2006;4:1424-1426. (Pubitemid 43756731)
17. Madsen EH, Schmidt EB, Maurer-Spurej E, Kristensen SR. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008;19:335-341.
18. Dyszkiewicz-Korpanty A, Olteanu H, Frenkel EP, Sarode R. Clopidogrel anti-platelet effect: An evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100). Platelets 2007;18:491-496. (Pubitemid 350034851)
19. Shenkman B, Einav Y, Salomon O, Varon D, Savion N. Testing agonist-induced platelet aggregation by the Impact-R [Cone and plate(let) analyzer (CPA)]. Platelets 2008;19:440-446.
20. Gouya G, Jilma B, Niel M, Eichelberger B, Wolzt M, Panzer S. Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: A double blind randomized placebo controlled trial. Platelets 2009;20:171-176.
21. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781-788. (Pubitemid 44883819)
22. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007;18:199-206. (Pubitemid 46744118)
23. Kalb ML, Potura L, Scharbert G, Kozek-Langenecker SA. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009;20:7-11.
24. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 2003;307:969-976.
25. Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, Catozzi L, Malagutti P, Anselmi M, Vassanelli C, Scapoli G, Ferrari R. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: Insights into the STRATEGY Study. J Am Coll Cardiol 2006;48:2178-2185. (Pubitemid 44873056)
26. Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, McIntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993;81:1263-1276.
27. Williams MS, Ng'alla LS. Heparin therapy leads to platelet activation and prolongation of PFA-100 closure time. J Cardiovasc Pharmacol Ther 2005;10:273-280.
28. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-1621.
29. Sakariassen KS, Ottenhof-Rovers M, Sixma JJ. Factor VIIIvon Willebrand factor requires calcium for facilitation of platelet adherence. Blood 1984;63:996-1003. (Pubitemid 14100897)
30. Judge HM, Buckland RJ, Holgate CE, Storey RF. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses. Platelets 2005;16:398-407.
31. Knobl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P. Anti von Willebrand Factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009; in press.